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Abstract
Objectives To determine whether the dose of inhaled
corticosteroids can be stepped down in patients with
chronic stable asthma while maintaining control.
Design One year, randomised controlled, double
blind, parallel group trial.
Setting General practices throughout western and
central Scotland.
Participants 259 adult patients with asthma receiving
regular treatment with inhaled corticosteroids at high
dose (mean dose 1430 g beclomethasone
dipropionate).
Interventions Participants were allocated to receive
either no alteration to their dose of inhaled
corticosteroid (control) or a 50% reduction in their
dose if they met criteria for stable asthma (stepdown).
Main outcome measures Comparison of asthma
exacerbation rates, asthma related visits to general
practice and hospital, health status measures, and
corticosteroid dosage between the two groups.
Results The proportions of subjects with asthma
exacerbations were not significantly different
(stepdown 31%, control 26%, P=0.354). Similarly, the
numbers of visits to general practice or hospital and
the disease specific and generic measures of health
status over the one year period were not significantly
different. On average the stepdown group received
348 g (95% confidence interval 202 g to 494 g) of
beclomethasone dipropionate less per day than the
controls (a difference of 25%), with no difference in
the annual dose of oral corticosteroids between the
two treatment regimens.
Conclusions By adopting a stepdown approach to
the use of inhaled steroids at high doses in asthma a
reduction in the dose can be achieved without
compromising asthma control.
Introduction
Inhaled corticosteroids are highly effective in the treat-
ment of asthma.1–3 Their potential for causing dose
related side effects has, however, led to asthma
management guidelines recommending a reduction in
their dose once asthma control is established.2–4
Research evidence shows that a reduction can be
achieved in the short term, in mild disease, or with the
addition of other antiasthma treatments.5–8 The clinical
implications of this approach to treatment have not,
however, been tested by means of a randomised
controlled trial over the longer term or for patients
with moderate to severe disease. We therefore tested
the hypothesis that a stepdown approach to the use of
inhaled corticosteroids at high dosage can be adopted
safely in adults with chronic stable asthma.
Methods
Participants
We recruited 259 participants from general practices
throughout western and central Scotland. Participants
were aged 18 years and older, had a diagnosis of
asthma9 for at least one year, and were being treated
with at least 800 g inhaled beclomethasone
dipropionate daily (or budesonide or fluticasone
propionate at equivalent dosage).We excluded patients
if they had required oral corticosteroids or visited gen-
eral practice or hospital for asthma in the preceding
two months. Other exclusion criteria included inability
to use a peak flow meter; treatment with immunosup-
pressive drugs; serious illness; alcohol, drug, or
substance misuse; pregnancy; and participation in
other research in the past six months. Participants gave
written informed consent.
Study design
We conducted a multicentre, randomised, double
blind, parallel group trial over a period of one year.
Protocol, assignment, and masking
Run-in—We collected baseline data during a one
month run-in period. Before run-in, we allocated
participants a dose of beclomethasone dipropionate
(metered dose inhaler) or fluticasone propionate
(metered dose inhaler or dry powder inhaler;
Accuhaler, GlaxoSmithKline, Middlesex, United King-
dom) according to their use of inhaled corticosteroids
before the study. A spacer device (Volumatic,
GlaxoSmithKline, Middlesex, United Kingdom) was
provided for patients using a metered dose inhaler.
Randomisation visit—After run-in, we used a compu-
ter generated allocated randomisation sequence, strati-
fied by centre, to randomise participants to either a
reduction in their dose of inhaled corticosteroid (step-
down) or a sham reduction (control). Randomisation
numbers were issued on a sequential basis, and the
randomisation code was withheld from the investiga-
tors until completion of the study.
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Study inhalers—A central pharmacy produced two
packs of inhaled corticosteroid for each participant
according to the randomisation code. The packs were
identical in appearance and labelled either “usual
dose” or “reduced dose” (box).
Study visits—At randomisation, participants
received a pack containing inhaled corticosteroids at
usual dosage. Subsequent study visits took place at
three, six, nine, and 12 months, when asthma control
was assessed and an inhaler pack issued accordingly
(good control=reduced dose, poor control=usual dose).
Thus the dosage of inhaled corticosteroid remained
unaltered in the control group, and in the stepdown
group it went down or up according to asthma control.
Assessment of asthma control
Patients kept diaries of their peak expiratory flow
during run-in and for two weeks before each study visit.
Measurements were made morning and evening
(Mini-Wright peak flow meter, Clement Clarke,
Harlow, United Kingdom) and the best of three
attempts recorded. A “target” peak flow was calculated
for each participant, defined as 80% of the mean peak
flow during run-in.
We calculated a short asthma morbidity score at
each visit.10 This was derived from a four item
questionnaire relating to asthma symptoms and use of
a reliever inhaler over the preceding month. Scores
ranged from 0 (perfect control) to 8 (very poor
control).
Study criteria for good control were an asthma
morbidity score of 2 or less, no visits for asthma to gen-
eral practice or hospital since the previous visit, and a
peak flow greater than or equal to the “target” peak
flow on eight of the past 14 days. If peak flow data were
not available we used the first two criteria.
Management of worsening asthma
Participants were advised to use their reliever inhaler
on a regular basis and to seek medical attention if
symptoms failed to settle or their peak flow dropped to
below 70% of the mean run-in peak flow. The
attending doctor treated exacerbations with a course of
oral corticosteroids as considered necessary.
Objectives and outcome measures
The primary objective was to compare between the two
groups the proportion of participants who had an
exacerbation of their asthma. Secondary objectives
were to determine in the stepdown group the
proportion of participants achieving a 50% reduction
in their daily dose of inhaled corticosteroids while
maintaining asthma control, and to compare between
the two groups the number of asthma related events,
the total dose of inhaled and oral corticosteroid
administered, and any changes in health status over the
one year period.
An asthma exacerbation was defined as any
worsening of asthma requiring a course of oral
corticosteroids. Asthma related events were defined as
any admission to hospital, attendance at accident and
emergency departments, visit to general practice, or
home visit by the general practitioner, with worsening
asthma. Details of asthma events were confirmed
through general practice records. Details of courses of
oral corticosteroid and any use of additional inhaled
corticosteroids, or “doubling up” of study inhalers were
recorded. Participants graded compliance with study
inhalers on a scale of 1 (poor) to 10 (excellent).11
Participants completed two measures of health
status, the St George’s respiratory questionnaire and
EuroQol, at each visit.12 13 A score measuring the
impact of chest disease on daily life and wellbeing was
derived from the St George’s respiratory question-
naire. This ranged from 0 (minimum impact) to 100
(maximum impact). The EuroQol is a generic measure
of health related quality of life, including a visual
analogue scale, ranging from 0 (worst imaginable
health state) to 100 (best imaginable health state).
Forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC) were measured before
and after administration of inhaled salbutamol (200 g
from a volumatic spacer) by using a dry spirometer
(Vitalograph, Buckinghamshire, United Kingdom),
and the best of three attempts was recorded.
Analysis
We estimated that 15% of patients with well controlled
asthma might be expected to experience an exacerba-
tion of asthma over a one year period.14 15 We aimed to
recruit 120 patients per group, to give the trial 80%
power at a significance level of 5% to detect a clinically
relevant difference in exacerbation rate of 15%
between the two groups.
We collected data regarding asthma exacerbations,
asthma related events, and use of oral corticosteroids
for all participants for the full one year period and per-
formed intention to treat analyses. Analysis of inhaled
corticosteroid use and health status was limited to
patients who had complete data for at least one visit
after randomisation.
We used the 2 test to analyse asthma exacerbations
and asthma events, with corresponding odds ratio and
95% confidence interval. We carried out a subgroup
analysis of asthma exacerbations after excluding
participants receiving treatment with long acting 2
Study inhaler packs
We allocated all participants to a starting dose of
inhaled corticosteroid according to their use of
inhaled corticosteroids before the study—for example,
1000 g beclomethasone dipropionate. Starting doses
of inhaled corticosteroids were allocated from
beclomethasone dipropionate (1000 g, 1500 g, or
2000 g daily) or fluticasone propionate (500 g,
1000 g, 1500 g, or 2000 g daily). Study inhaler
packs were then made up for each participant
according to which treatment they had been allocated
to as follows.
Stepdown group
Usual dose pack: contains the starting dose of inhaled
corticosteroid—for example, 1000 g beclomethasone
dipropionate
Reduced dose pack: contains 50% of the starting dose
of inhaled corticosteroid—for example, 500 g
beclomethasone dipropionate
Control group
Usual dose pack: contains the starting dose of inhaled
corticosteroid
Reduced dose pack: contains the starting dose of
inhaled corticosteroid
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agonists. We used a Wilcoxon test to compare use of
oral corticosteroids between the two groups.
We calculated an annual dose of inhaled cortico-
steroids for each participant and expressed this in units
of beclomethasone dipropionate (by using a conver-
sion rate of 2 mg beclomethasone dipropionate=1 mg
fluticasone propionate). Where participants were with-
drawn before completing one year follow up we calcu-
lated an annual equivalent dose from the average daily
dose. We used a t test and 95% confidence interval for
the difference of two means for analysis.
For the St George’s respiratory questionnaire, the
short asthma morbidity score, and the EuroQol visual
analogue scale we expressed the worst score recorded
during follow up as a change from baseline and
compared scores between the two groups by using a t
test and 95% confidence interval for difference in
means.
Results
Between May 1999 and October 2001 we randomised
259 participants (aged 18 to 86 years) to the trial, and
212 (82%) completed one year follow up. We analysed
data from all patients for the primary outcome (figure).
The groups were similar with regard to baseline demo-
graphics and clinical characteristics (table 1). Alto-
gether 109/130 (84%) of the stepdown group and
105/129 (81%) of the control group met criteria for
good control, and these were issued with a “reduced
dose” pack of inhaled corticosteroids at some point
during the study. Sixty four (49%) participants in the
stepdown group completed the study taking a reduced
dose of inhaled corticosteroid (50% of starting dose)
and with good control. Both groups reported good
compliance with study inhalers (mean score 10/10).
Asthma exacerbations and asthma related events
We found no significant difference in the rate of
asthma exacerbation or asthma events between the two
groups (table 2). Forty participants (31%) of the
stepdown group and 33 (26%) of the control group
experienced at least one asthma exacerbation over the
one year period (odds ratio 1.29, 95% confidence
interval 0.75 to 2.23, P=0.354). A visit to general prac-
tice was the most common event to occur in both
groups (stepdown 35% (45 participants), control group
32% (41 participants); odds ratio 1.14, 0.68 to 1.91,
P=0.629). Home visits, attendances in accident and
emergency wards, and admissions to hospital were rare
events in both groups.
Health status measures and short asthma morbidity
score
The differences between the two groups in the mean
change in score from baseline were not significantly
different for the St George’s respiratory questionnaire
(difference 0.13, 95% confidence interval − 2.76 to
3.03, P=0.929), the short asthma morbidity score (0.16,
− 0.34 to 0.66, P=0.537), or the EuroQol visual
analogue scale (2.32, − 1.67 to 6.32, P=0.252) (table 3).
Annual corticosteroid dose
Table 4 shows data on use of inhaled corticosteroids
for 243 participants (stepdown 120, control 123). We
found a significant difference in the mean annual dose
of inhaled corticosteroid between the two groups
(stepdown 390 mg beclomethasone dipropionate, con-
trol 517 mg beclomethasone dipropionate, P < 0.001;
mean difference − 127 mg, − 180 to − 74). This repre-
sents a mean daily saving of 348 g of beclomethasone
dipropionate for participants in the stepdown group
(95% confidence interval 202 to 494).We found no sig-
nificant difference in the mean annual dose of oral
corticosteroid (prednisolone) between the two groups
(stepdown 117 mg, control 109 mg; P=0.252).
Adverse events—Fourteen participants (seven in each
group) experienced a serious adverse event during the
study, and three events were asthma related. These
three events occurred in the stepdown group and were
all non-fatal asthma exacerbations requiring admission
to and treatment in hospital. Of the three participants
experiencing an asthma related adverse event, only
one was taking a reduced dose of inhaled cortico-
steroid at the time of the event whereas the dose of the
other two had not been reduced at any time before the
event.
Discussion
Our study provides evidence that, by using the
procedure outlined, adopting a stepdown approach to
1410 patients invited from 81 practices
(total practice population 462,526)
Positive responses (n=473)
Unable to contact =15
Assessed for eligibility =458
Entered run-in (n=308)
Randomised (n=259)
Allocated to stepdown
(n=130)
Lost to follow up (n=0)
Discontinued intervention (n=24)
Asthma event =9
Non-asthma event =1
Died =1
Refusal or did not attend =12
Other =1
Analysed for primary outcome
(n=130)
Excluded (n=150)
Not meeting eligibility criteria =114
Unable or unwilling to give consent =33
Other =3
Excluded (n=49)
Not meeting eligibility criteria =26
Unable or unwilling to participate or
did not attend =19
Other =4
Allocated to control
(n=129)
Analysed for primary outcome
(n=129)
Lost to follow up (n=0)
Discontinued intervention (n=22)
Asthma event =8
Non-asthma event =1
Protocol violation =1
Refusal or did not attend =8
Other =4
Flow of participants
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inhaled corticosteroids is safe in patients with stable
asthma who receive regular treatment with at least
1000 g beclomethasone dipropionate daily. This is an
important finding as it supports the recommendations
made in current asthma guidelines and can be used to
inform future evidence based practice.
Inhaled corticosteroids are widely accepted as the
treatment of choice for patients with chronic asthma.1–3
However, they have been associated with a number of
dose related side effects including bruising, cataract for-
mation, glaucoma, reduced bone density, and adrenal
suppression.1 4 16 The therapeutic response may plateau
at doses below 1000 g of inhaled beclomethasone
dipropionate (500 g of fluticasone propionate),17–19 and
it should therefore be possible for a substantial
proportion of patients receiving inhaled corticosteroids
at high dosage to reduce their dose, thereby reducing
the risk of side effects while maintaining control.
Limitations of the study
Inhaled long acting 2 agonist have been shown to
facilitate a reduction of inhaled corticosteroids in
asthma patients.7 8 In our study 48 (37%) participants
in the stepdown group and 39 (30%) controls were
receiving regular treatment with these drugs. A
subgroup analysis after these patients were excluded
did not show a significant difference between the two
groups for the main outcome measure of asthma exac-
erbation (34% versus 24%, P=0.148). However, owing
to the smaller numbers the power of this analysis to
detect a clinically significant difference would have
been reduced. A much larger study would be required
to tease out the effects, if any, that polypharmacy might
have on stepping down inhaled corticosteroids.
We compared two management strategies for
inhaled corticosteroid use in asthma: a “do nothing”
approach, where the dose of inhaled steroid remained
unaltered over the one year period, and a “stepdown”
approach, where the dose was reduced by 50% only if
criteria for asthma stability were met. The differences
between the two strategies in the rate of asthma
exacerbations or general practice visits or in measures
of health related quality of life were non-significant.We
also found no significant differences in home visits,
attendances at accident and emergency departments,
or hospital admissions; as these were rare events for
both groups, however, a larger study would be required
to provide sufficient power to detect a difference in the
rate of these outcomes.
It is possible that inclusion in a trial leads to
improved compliance with medications. If one
assumes this to have been the case in our study then a
degree of caution should be adopted in translating our
experience to the clinical setting.
Table 1 Baseline characteristics of the two groups in the randomised controlled trial.
Values are numbers (%) of patients unless otherwise indicated
Characteristic
Stepdown group
(n=130)
Control group
(n=129)
Age in years (SD) 52.8 (14.5) 55 (15.2)
Sex:
Male 54 (41.5) 54 (41.9)
Female 76 (58.5) 75 (58.1)
Smoking status:
Current smoker 16 (12.3) 17 (13.2)
Former smoker 44 (33.8) 49 (38.0)
Never smoker 70 (53.9) 63 (48.8)
Duration of asthma in years (SD) 19 (14.9) 19 (16.4)
Run-in daily dose of inhaled corticosteroid
Beclomethasone dipropionate:
1000 g 53 (40.8) 71 (55.0)
1500 g 10 (7.7) 5 (3.9)
2000 g 4 (3.1) 5 (3.9)
Fluticasone propionate:
500 g 22 (16.9) 12 (9.3)
1000 g 34 (26.2) 30 (23.3)
1500 g 4 (3.1) 4 (3.1)
2000 g 3 (2.3) 2 (1.6)
Daily baseline dose (g) of inhaled corticosteriod as
beclomethasone equivalent (SD)
1461.5 (657.7) 1399.2 (623.1)
Other antiasthma medication:
Long acting 2 agonist 48 (36.9) 39 (30.2)
Leukotriene receptor antagonist 5 (3.9) 4 (3.1)
Theophylline 12 (9.2) 10 (7.8)
Anticholinergic 8 (6.15) 12 (9.3)
Respiratory function:
Target peak expiratory flow (n=239) in litres/minute (SD) 324 (84.6) 314 (81.4)
Pre-salbutamol FEV1 (n=257) as % of predicted value (SD) 80.3 (19.2) 80.1 (18.6)
Post-salbutamol FEV1 (n=257) as % of predicted value (SD) 85.5 (18.4) 85.3 (17.9)
Health status measures:
Short asthma morbidity score (SD) 1.1 (1.3) 1.2 (1.3)
St George’s respiratory score (n=254) (SD) 24.7 (16.8) 25.0 (16.4)
EuroQol visual analogue scale (n=237) (SD) 76.8 (14.5) 73 (16.8)
FEV1=forced expiratory volume in one second.
Table 2 Asthma exacerbations and asthma related events in the two groups. Values are numbers (%) of patients
Stepdown group
(n=130)
Control group
(n=129)
Odds ratio
(95% CI)
P value
(2 test)
Asthma exacerbations 40 (31) 33 (26) 1.29 (0.75 to 2.23) P=0.354
Asthma related events:
Visit to general practice 45 (35) 41 (32) 1.14 (0.68 to 1.91) P=0.629
Home visit by general practitioner 3 (2) 6 (5) 0.48 (0.12 to 1.98) P=0.304
Visit to accident and emergency department 2 (2) 1 (1) 2 (0.18 to 22.3) P=0.567
Admission to hospital 4 (3) 1 (1) 4.06 (0.45 to 36.86) P=0.179
Table 3 Health status of the two groups as measured by validated instruments and short asthma morbidity score
Stepdown group Control group Difference (95% CI) P value (t test)
St George’s respiratory questionnaire (n=110) (n=119)
Difference of maximum score from baseline (SD) 7.53 (10.68) 7.40 (11.95) 0.13 (−2.76 to 3.03) P=0.929
Short asthma questionnaire morbidity score (n=120) (n=122)
Difference of maximum score from baseline (SD) 1.59 (1.96) 1.43 (2.00) 0.16 (−0.34 to 0.66) P=0.537
EuroQol (n=108) (n=111)
Difference of lowest score from baseline (SD) −7.00 (13.04) −9.32 (16.69) 2.32 (−1.67 to 6.32) P=0.252
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Strengths of the study
This was a pragmatic trial with a complex interven-
tion.20 We enrolled patients typical of those managed in
primary care and used outcome measures achievable
in the primary care setting.21 22 Our findings are there-
fore pertinent to the population for which stepdown is
recommended, and our management approach can be
adopted easily by primary care teams, which are
responsible for the care of most asthma patients. We
recruited from six health board areas, across a wide
range of deprivation categories and rural and urban
settings. We believe therefore that our findings can be
generalised to the population at large. As our study was
limited to patients receiving high doses of inhaled
corticosteroids our findings may not be reproducible
in patients with milder disease who receive lower doses.
Not all patients allocated to the stepdown regimen
received a reduction in their dose of inhaled
corticosteroids. However, sufficient numbers (83%)
received the intervention for the study to be valid, and
the inclusion of patients who did not makes this a true
intention to treat analysis, reflecting the reality of man-
aging this group of patients in practice. We included
smokers in our study, a group often excluded from
trials but estimated to represent up to 30% of adult
asthma patients.23 A proportion of the smokers may
have had mixed disease with an element of irreversible
airflow obstruction, but any influence this may have
had on the results is likely to be minimal because of the
small numbers involved.
Previous research has shown that the dose of
inhaled corticosteroids can be reduced in patients with
mild disease.5 Results from other trials show that it
should also be possible to reduce the dose of inhaled
corticosteroids in moderate or severe asthma without
jeopardising control.6 7 However, these studies have
been limited by short term follow up and have used an
“open label” design for reducing the dose of inhaled
corticosteroids. As the stepdown approach to using
inhaled corticosteroids in asthma has been adopted
into international asthma guidelines largely as a result
of expert opinion our study provides valuable evidence
in support of this management strategy.
Over the one year period, participants in the step-
down group received, on average, 348 g (25%) less
inhaled beclomethasone dipropionate per day than
controls, and the use of oral corticosteroids did not
differ significantly between the two groups. This
finding shows that a stepdown approach to inhaled
corticosteroids can reduce the risk of steroid related
side effects in this group of patients.
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